Qiheshengke Biotechnology
齐禾生科
Qiheshengke Biotechnology (齐禾生科) is a Suzhou-based gene-editing biotech company co-founded in 2021 by a "top-tier" scientific team including Kevin Zhao, a Harvard-trained researcher who studied under David Liu, the inventor of base editing and prime editing . The company focuses on developing novel gene-editing technologies for agricultural applications, building on work that produced the world's first CRISPR-Cas9 plant in 2013 . It has raised two major rounds to date: an over-100-million-yuan Pre-A round in April 2023 led by Cende Capital with participation from Gaorong Ventures, Source Code Capital and others , followed by an over-200-million-yuan Series A in late 2024 led by the Beijing Medical and Health Industry Investment Fund . The company has also published original research, including a new deaminase base-editing system developed in collaboration with the Chinese Academy of Sciences' Institute of Genetics and Developmental Biology .
AI-generated — may contain errors, please verify.
Coverage
Rong Report | HT Aero, Xiwang, Helixon and Others Close Major Funding Rounds; Moonshot AI and Momenta Release Leading Models
Major Funding + Leading Model + Mass Production
Rongbao | Karl Dynamics, Aerofugia, StarsComm, and ImmuPeak Kick Off the Year with Major Funding Rounds
Leading the industry into a new era.
Rongbao | Multiple autonomous driving, nuclear fusion, gaming, and innovative drug companies raise hundreds of millions of RMB in funding
From commercial deployment to world-first breakthroughs, innovation never stands still.
Rongbao | Multiple Products Debut at Shanghai Auto Show, AI Drug Lands Major Licensing Deal, Mingming Henmang and Geekplus Race Toward Hong Kong IPOs
New product launches, major licensing deals, accelerated clinical trials...
Gaorong Report · 2025 | Innovative Drugs, Agri-Tech, AI Content Platforms Close Funding Rounds; Gaorong Earns Multiple Accolades
Innovation as the sail, hard work as the oar.
Qihe Biotech Closes Over RMB 200 Million Series A to Accelerate Gene Editing R&D and Commercialization
Develop novel gene-editing technologies to create exceptional biological traits and products.
When a "Top-Tier" Gene-Editing Scientist Team Starts Caring About Seeds, Grains, and Vegetables | Gaorong Ventures
Let harvests be not only nature's gift, but also the fruit of technology.
Chip companies, surgical robots, and consumer tech brands close new funding rounds | Rongbao · June
Notable developments to watch in June.
Chip/Consumer Electronics/Gene Editing Firms Raise New Funding; Quantum Computers, Micro-Display Chips Achieve Global Leadership | Rongbao · April
Targeting international advanced standards.
Qihe Biotech Closes Over 100 Million Yuan Pre-A Round to Accelerate Development and Application of Novel Gene-Editing Technologies
Accelerate the commercialization of gene-edited breeding.
